Improving cancer immunotherapy by targeting IL-1

Zhilan Xiao; Shubhra Singh; Manisha Singh

doi:10.1080/2162402X.2021.2008111

Improving cancer immunotherapy by targeting IL-1

Zhilan Xiao, Shubhra Singh, Manisha Singh

Lymphoma-Myeloma

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Interleukin-1 (IL-1) is an inflammatory cytokine associated with tumor invasiveness and metastasis. We recently found that baseline IL-1 in melanomas promoted resistance to immunotherapy by creating an immunosuppressive tumor microenvironment and that IL-1 produced in response to CD40 agonist also induced resistance to therapy. Here, we discuss how naturally occurring and immunotherapy-induced IL-1 in tumors causes immune suppression and resistance to immunotherapy, and we discuss targeting the IL-1 pathway to enhance the efficacy of immunotherapy.

Original language	English (US)
Article number	2008111
Journal	OncoImmunology
Volume	10
Issue number	1
DOIs	https://doi.org/10.1080/2162402X.2021.2008111
State	Published - 2021

Keywords

cancer
IL-1
immunotherapy
Inflammation

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.1080/2162402X.2021.2008111

Cite this

@article{1e46e768f0dd4736a744c0a5b9fdf4c2,

title = "Improving cancer immunotherapy by targeting IL-1",

abstract = "Interleukin-1 (IL-1) is an inflammatory cytokine associated with tumor invasiveness and metastasis. We recently found that baseline IL-1 in melanomas promoted resistance to immunotherapy by creating an immunosuppressive tumor microenvironment and that IL-1 produced in response to CD40 agonist also induced resistance to therapy. Here, we discuss how naturally occurring and immunotherapy-induced IL-1 in tumors causes immune suppression and resistance to immunotherapy, and we discuss targeting the IL-1 pathway to enhance the efficacy of immunotherapy.",

keywords = "cancer, IL-1, immunotherapy, Inflammation",

author = "Zhilan Xiao and Shubhra Singh and Manisha Singh",

note = "Funding Information: This work was supported by the Department of Defense Idea Award CA160521 (to M.S.) and The University of Texas MD Anderson Cancer Center Specialized Program of Research Excellence in Melanoma (P50CA093459 to M.S.) Publisher Copyright: {\textcopyright} 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2021",

doi = "10.1080/2162402X.2021.2008111",

language = "English (US)",

volume = "10",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "1",

}

TY - JOUR

T1 - Improving cancer immunotherapy by targeting IL-1

AU - Xiao, Zhilan

AU - Singh, Shubhra

AU - Singh, Manisha

N1 - Funding Information: This work was supported by the Department of Defense Idea Award CA160521 (to M.S.) and The University of Texas MD Anderson Cancer Center Specialized Program of Research Excellence in Melanoma (P50CA093459 to M.S.) Publisher Copyright: © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.

PY - 2021

Y1 - 2021

N2 - Interleukin-1 (IL-1) is an inflammatory cytokine associated with tumor invasiveness and metastasis. We recently found that baseline IL-1 in melanomas promoted resistance to immunotherapy by creating an immunosuppressive tumor microenvironment and that IL-1 produced in response to CD40 agonist also induced resistance to therapy. Here, we discuss how naturally occurring and immunotherapy-induced IL-1 in tumors causes immune suppression and resistance to immunotherapy, and we discuss targeting the IL-1 pathway to enhance the efficacy of immunotherapy.

AB - Interleukin-1 (IL-1) is an inflammatory cytokine associated with tumor invasiveness and metastasis. We recently found that baseline IL-1 in melanomas promoted resistance to immunotherapy by creating an immunosuppressive tumor microenvironment and that IL-1 produced in response to CD40 agonist also induced resistance to therapy. Here, we discuss how naturally occurring and immunotherapy-induced IL-1 in tumors causes immune suppression and resistance to immunotherapy, and we discuss targeting the IL-1 pathway to enhance the efficacy of immunotherapy.

KW - cancer

KW - IL-1

KW - immunotherapy

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=85120172731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120172731&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2021.2008111

DO - 10.1080/2162402X.2021.2008111

M3 - Article

C2 - 34858734

AN - SCOPUS:85120172731

SN - 2162-4011

VL - 10

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - 2008111

ER -

Improving cancer immunotherapy by targeting IL-1

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this